Overview

An Evaluation of 9MW1911 Injection in Healthy Subjects

Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.